Aduro pancreatic cancer combo fails Phase IIb test

Aduro Biotech Inc. (NASDAQ:ADRO) fell $1.78 (17%) to $8.91 on Monday after it said a combination of CRS-207 and GVAX Pancreas cancer

Read the full 226 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE